Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment

Exclusion Criteria

• •Hypersensitive to apomorphine hydrochloride or any of the ingredients of Apokyn® (notably sodium metabisulfite)
• •Hypersensitive to trimethobenzamide or any of the ingredients of Tigan®
• •Previous treatment with Apokyn®
• •Participation in any other clinical trial within 14 days of the present trial
• •Contraindications to Apokyn® or Tigan®
• •Currently taking, or likely to need to take at any time during the course of the study, any 5HT3 antagonist (ondansetron, alosetron, granisetron, palonosetron or dolasetron)
• •Malignant melanoma or a history of previously treated malignant melanoma
• •Pregnancy or breast feeding
• •Receipt of any investigational (i.e. unapproved) medication within 30 days of starting the present trial
• •Any significant medical disorder, condition, concomitant medication or psychiatric disorder according to DSM-IV criteria which would, in the opinion of the investigator, represent a hazard to the subject or prevent the subject from completing the trial